Skip to content

Advertisement

  • Oral presentation
  • Open Access

Mevalonate kinase deficiency: an early onset inflammatory bowel disease?

  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 9,
  • 10,
  • 11,
  • 12,
  • 13 and
  • 11, 13
Pediatric Rheumatology201513(Suppl 1):O56

https://doi.org/10.1186/1546-0096-13-S1-O56

Published: 28 September 2015

Keywords

  • Inflammatory Bowel Disease
  • Endoscopic Feature
  • Abdominal Adhesion
  • Mevalonate Kinase Deficiency
  • Heterozygote Mutation

Introduction

Mevalonate kinase deficiency (MKD) is a rare autoinflammatory, autosomal-recessive defect on MVK gene. Clinical spectrum ranges from recurring febrile attacks to malformations and neurologic disorders. Gastrointestinal symptoms are cardinal. Severe gastrointestinal involvement has been described at the onset.

Objective

To analyse severe gastrointestinal events (SGE) complicating MKD.

Patients and methods

Retrospective observational French cohort of MKD patients. SGE were defined as complicated inflammatory involvement, requiring an abdominal surgery and/or enteral/parenteral nutrition. Data were collected from clinical charts provided by the members of the Francophone Society for Paediatric Rheumatism and Inflammatory Diseases (SOFREMIP).

Results

From a 53-patient cohort, nine presented a SGE (17%). From these, disease onset median age was 1.0 months (0-12); one patient deceased (22 months) from a non-gastrointestinal event. Compound heterozygote mutations were found in 7/8, being Val377Ile the commonest (6/8). The main symptoms during febrile attacks were: diarrhoea (100%, 7/7), lymphadenopathy (89.9%, 8/9), skin lesions, joint pain (85.7%, 6/7 each), aphtous ulcers, abdominal pain (83.3%, 5/6 each), splenomegaly (66.7%, 6/9), hepatomegaly (62.5%, 5/8) and vomiting (57.1%, 4/7). Median mevalonic aciduria: 23.05 mmol/mol of creatinine (P25=13.7; P75=55.5); median MK activity: 2.2% (P25=1.0; P75=24.0). The significant co-morbidities found in SGE patients in comparison with the global cohort were: failure-to-thrive in 85.7% (6/7), pulmonary diseases in 37.5% (3/8) and feeding disorders in 28.6% (2/7) (p<0.05).

Severe gastrointestinal involvement was the first event in 6% (3/50), representing 43% (3/7) of patients with severe gastrointestinal disease: abdominal adhesions (66.6%, 6/9) and colitis/enterocolitis (4/9, 44.4%) were mainly found. 87.5% (7/8) needed surgery and 44.4% (4/9) required enteral/parenteral nutrition. Despite digestive resection, disease progression remained; two patients needed re-intervention due to surgical complications. Aphtous/ulcerative damage was the main endoscopic feature (4/9, 44.4%). The most consistent microscopic finding was lymphocytic infiltrates. IL-1 antagonists were the most used/effective treatment (4/9), resulting in with complete remission in all three patients with data available.

Conclusion

MKD severe gastrointestinal involvement presentation has a non-negligible frequency. It usually appears as an aphtous/ulcerative disease involving any part of the digestive tract or as abdominal adhesions, frequently requiring surgery. The treatment with IL-1 antagonists resulted in complete remission in a majority of treated patients. Thus, MKD should be added to the list of monogenic early-onset inflammatory bowel disease.

Authors’ Affiliations

(1)
Hospital Prof. Doutor Fernando Fonseca, E.P.E., Paediatrics, Amadora, Portugal
(2)
Department of Anatomic Pathology, Hôpital Robert Debré, APHP, Paris, France
(3)
Paediatric Department, CHU Limoges, Limoges, France
(4)
Department of Anatomic Pathology, CHU Limoges, Limoges, France
(5)
Department of Paediatric Haematology and Oncology, Hôpital d'Enfants Armand-Trousseau, Paris, France
(6)
Paediatric Department, C.H.U. Caen, Caen, France
(7)
Department of Anatomic Pathology, C.H.U. Caen, Caen, France
(8)
Rheumatology Department, C.H.U. Rouen, Rouen, France
(9)
Department of Paediatric Immunology and Haematology, C.H.U. d'Angers, Angers, France
(10)
Paediatric Department, Centre Hospitalier Robert Bisson, Lisieux, France
(11)
Hôpital Robert Debré, APHP, General Paediatric Department, Infectious Diseases and Internal Medicine, Paris, France
(12)
Department of Paediatric Gastroenterology, Hepatology and Nutrition, Groupe Hospitalier Necker-Enfants Malades, APHP, Paris, France
(13)
Groupe Hospitalier Necker-Enfants Malades, Department of Paediatric Immunology Haematology and Rheumatology, APHP, INSERM U768 and Imagine Foundation, Paris, France

Copyright

© Martins et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement